Anticoagulation in Rheumatic Heart Disease with Atrial Fibrillation
Patients with rheumatic heart disease and atrial fibrillation must receive warfarin (vitamin K antagonist) with a target INR of 2.0-3.0, not direct oral anticoagulants (DOACs).
The Evidence is Clear and Definitive
Rheumatic heart disease, particularly rheumatic mitral stenosis, represents one of the highest-risk conditions for stroke in atrial fibrillation patients. Multiple guidelines consistently classify this as a Class I, Level A recommendation for warfarin therapy 1, 2, 3, 4, 5.
The 2014 AHA/ACC/HRS guideline explicitly states that DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) are not recommended in patients with moderate or severe mitral stenosis or mechanical heart valves 6. The 2020 ACC/AHA Valvular Heart Disease guideline reinforces this, specifying that patients with rheumatic mitral stenosis and atrial fibrillation should receive oral anticoagulation with a vitamin K antagonist, not DOACs 7.
Why DOACs Fail in Rheumatic Heart Disease
The landmark INVICTUS trial (2022) definitively answered this question 8. In 4,531 patients with rheumatic heart disease-associated atrial fibrillation, rivaroxaban was inferior to warfarin:
- Restricted mean survival time was 76 days shorter with rivaroxaban (95% CI: -121 to -31 days; P<0.001)
- Death rates were higher with rivaroxaban (72 fewer days of survival; 95% CI: -117 to -28)
- No bleeding advantage was seen with rivaroxaban
- The trial was stopped early due to clear inferiority
This is not a marginal difference—this is a clinically significant increase in cardiovascular events and death with DOAC therapy in this population 8, 9.
The Practical Algorithm
Step 1: Confirm Rheumatic Heart Disease
- Echocardiographic documentation of rheumatic valve disease (particularly mitral stenosis with characteristic leaflet thickening, commissural fusion, restricted leaflet motion)
- Any degree of rheumatic mitral stenosis qualifies as high-risk
Step 2: Initiate Warfarin
- Target INR: 2.0-3.0 (target 2.5) 1, 2, 4, 5
- Check INR weekly during initiation 1, 2, 6, 4
- Check INR monthly when stable 1, 2, 6, 4
Step 3: Do NOT Use DOACs
- This is a Class III: Harm recommendation for mechanical valves 6
- The INVICTUS trial extends this contraindication to rheumatic heart disease 8
- Even after bioprosthetic mitral valve replacement, recent data suggests warfarin remains appropriate, though this is evolving 10
Critical Pitfalls to Avoid
Pitfall #1: Using CHA₂DS₂-VASc score to decide on anticoagulation
- Do NOT use risk scores in rheumatic heart disease patients
- Rheumatic mitral stenosis is automatically high-risk regardless of CHA₂DS₂-VASc score 1, 2, 3, 4
- These patients need warfarin, period
Pitfall #2: Switching to DOACs for "convenience"
- The INVICTUS trial showed higher mortality with rivaroxaban 8
- Convenience does not justify increased death risk
- INR monitoring challenges must be addressed through patient education, point-of-care testing, or telehealth—not by switching to DOACs
Pitfall #3: Assuming all valvular AF is the same
- The 2024 ESC guidelines distinguish between rheumatic disease and other valve pathology 11
- DOACs may be acceptable in non-rheumatic valvular AF (e.g., aortic stenosis, mitral regurgitation without stenosis)
- But rheumatic disease, especially mitral stenosis, is different
Special Considerations
If INR Control is Poor
- Optimize warfarin dosing and monitoring frequency
- Address adherence barriers (cost, access, education)
- Consider point-of-care INR testing
- Do NOT switch to DOACs 6—the evidence shows worse outcomes
Bridging for Procedures
- Use unfractionated heparin or low-molecular-weight heparin when warfarin must be interrupted 6
- Balance stroke risk (very high in rheumatic disease) against bleeding risk
- Resume warfarin as soon as safely possible
After Valve Replacement
- Mechanical valves: Warfarin indefinitely (INR ≥2.5 based on valve type) 1, 2, 6
- Bioprosthetic valves: Emerging data suggests warfarin may still be preferred over DOACs in rheumatic disease patients 10, though this requires further study
The Bottom Line
The evidence hierarchy is clear: multiple Class I guideline recommendations 1, 2, 3, 4, 5 supported by the most recent high-quality randomized trial 8 all point in the same direction. Warfarin is the only appropriate anticoagulant for patients with rheumatic heart disease and atrial fibrillation. DOACs are associated with increased mortality in this population and should not be used.